The minimalist, carry-anywhere device you didn't know you needed.
CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER‑NSCLC‑02 (GDF‑15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback